S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
NASDAQ:CMRX

Chimerix - CMRX Stock Forecast, Price & News

$1.93
-0.04 (-2.03%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.90
$1.99
50-Day Range
$1.81
$2.76
52-Week Range
$1.27
$7.42
Volume
1.10 million shs
Average Volume
3.11 million shs
Market Capitalization
$169.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60

Chimerix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
397.4% Upside
$9.60 Price Target
Short Interest
Healthy
4.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.49
Upright™ Environmental Score
News Sentiment
0.57mentions of Chimerix in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$37,200 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From $1.92 to ($0.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

195th out of 1,072 stocks

Pharmaceutical Preparations Industry

80th out of 534 stocks

CMRX stock logo

About Chimerix (NASDAQ:CMRX) Stock

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Stock News Headlines

Why Chimerix Stock Is Soaring Today - Benzinga
See More Headlines
Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Company Calendar

Last Earnings
8/08/2022
Today
10/05/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMRX
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.60
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+397.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-173,240,000.00
Net Margins
-17,482.40%
Pretax Margin
-17,482.40%

Debt

Sales & Book Value

Annual Sales
$1.98 million
Book Value
$0.79 per share

Miscellaneous

Free Float
80,438,000
Market Cap
$169.11 million
Optionable
Optionable
Beta
1.15

Key Executives

  • Mr. Michael A. Sherman M.B.A. (Age 56)
    CEO, Pres & Director
    Comp: $987.2k
  • Mr. Michael T. Andriole M.B.A. (Age 49)
    Chief Bus. Officer, Sec. & CFO
    Comp: $616.9k
  • Dr. Allen S. Melemed M.B.A. (Age 58)
    M.D., Chief Medical Officer
    Comp: $622.17k
  • Mr. David Jakeman CPA (Age 44)
    Exec. Director of Fin. & Accounting and Principal Accounting Officer
  • Dr. Roy W. Ware
    Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier
    Chief Science Officer
  • Ms. Michelle LaSpaluto
    VP of Strategic Planning & Investor Relations
  • Dr. Michael A. Alrutz (Age 52)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Dr. Joshua E. Allen
    Chief Technology Officer of Imipridones













CMRX Stock - Frequently Asked Questions

Should I buy or sell Chimerix stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings
or view top-rated stocks.

What is Chimerix's stock price forecast for 2022?

3 equities research analysts have issued 12 month price objectives for Chimerix's stock. Their CMRX share price forecasts range from $6.00 to $14.00. On average, they predict the company's share price to reach $9.60 in the next year. This suggests a possible upside of 392.3% from the stock's current price.
View analysts price targets for CMRX
or view top-rated stocks among Wall Street analysts.

How have CMRX shares performed in 2022?

Chimerix's stock was trading at $6.43 at the start of the year. Since then, CMRX shares have decreased by 69.7% and is now trading at $1.95.
View the best growth stocks for 2022 here
.

When is Chimerix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CMRX earnings forecast
.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) posted its quarterly earnings results on Monday, August, 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.03. The biopharmaceutical company earned $0.44 million during the quarter. Chimerix had a negative net margin of 17,482.40% and a negative trailing twelve-month return on equity of 171.05%.

What other stocks do shareholders of Chimerix own?
What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $1.95.

How much money does Chimerix make?

Chimerix (NASDAQ:CMRX) has a market capitalization of $170.86 million and generates $1.98 million in revenue each year. The biopharmaceutical company earns $-173,240,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146.

This page (NASDAQ:CMRX) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.